First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02
Status:
Completed
Trial end date:
2019-02-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determinate the efficacy and safety of the 3-drug induction
treatment (RVD; lenalidomide plus bortezomib plus dexamethasone)followed by randomized
autologous stem cell mobilization, autologous stem cell transplantation and lenalidomide
maintenance. Primary endpoint is the immunophenotypic remission rate.During the randomized
mobilization phase two active comparator arms Cyclophosphamide (CY)2g/m2 + Granulocyte-colony
stimulating factor(G-CSF) vrs G-CSF will be compared regarding efficacy, costs and safety.
Phase:
Phase 2
Details
Lead Sponsor:
Kuopio University Hospital
Collaborators:
Celgene Corporation Central Hospital of Kanta-Hame Helsinki University Central Hospital Jyväskylä Central Hospital Kainuu and Länsi-Pohja Central Hospital Kainuu Central Hospital, Kajaani Kanta-Häme Central Hospital Kymenlaakso Central Hospital Kotka Finland Mikkeli Central Hospital Oulu University Hospital Satakunta Central Hospital Tampere University Hospital Turku University Hospital